FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
-12.48%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$645M
AUM Growth
+$645M
(-36%)
Cap. Flow
-$231M
Cap. Flow
% of AUM
-35.86%
Top 10 Holdings %
Top 10 Hldgs %
87.27%
Holding
17
New
–
Increased
–
Reduced
5
Closed
2
Top Buys
No buys this quarter
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$76.3M |
| 2 |
Nuvalent
NUVL
|
$41.8M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
$39.3M |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
$24.3M |
| 5 |
AnaptysBio
ANAB
|
$24.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$6.05B
| $95.1M | 14.75% | 815,176 -653,807 | -45% | -$76.3M |
|
2
Apogee Therapeutics
APGE
$2.17B
| $76.5M | 11.87% | 2,048,647 | – | – |
|
3
Spyre Therapeutics
SYRE
$996M
| $64.8M | 10.06% | 4,018,101 | – | – |
|
4
Enliven Therapeutics
ELVN
$1.2B
| $63M | 9.78% | 3,202,798 | – | – |
|
|
5
Nuvalent
NUVL
$5.52B
| $51.6M | 8% | 727,563 -590,101 | -45% | -$41.8M |
|
6
Dianthus Therapeutics
DNTH
$759M
| $49M | 7.6% | 2,700,691 | – | – |
|
7
Viridian Therapeutics
VRDN
$1.5B
| $46.4M | 7.21% | 3,445,813 | – | – |
|
8
Scholar Rock
SRRK
$3.14B
| $44.2M | 6.85% | 1,374,031 -588,922 | -30% | -$18.9M |
|
9
Cogent Biosciences
COGT
$1.69B
| $37.3M | 5.79% | 6,225,641 | – | – |
|
|
ORKA
10
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $34.6M | 5.37% | 3,371,922 | – | – |
|
|
11
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $24.5M | 3.8% | 1,102,248 -1,092,093 | -50% | -$24.3M |
|
12
Astria Therapeutics
ATXS
$349M
| $19M | 2.94% | 3,554,129 | – | – |
|
|
ZBIO
13
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $15M | 2.32% | 1,892,806 | – | – |
|
14
Inhibikase Therapeutics
IKT
$134M
| $13.4M | 2.08% | 6,125,000 | – | – |
|
|
BCAX
15
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $10.2M | 1.59% | 784,170 -499,999 | -39% | -$6.51M |
|
|
16
AnaptysBio
ANAB
$569M
| – | – | -1,816,466 | Closed | -$24.1M |
|
|
17
Day One Biopharmaceuticals
DAWN
$769M
| – | – | -3,103,448 | Closed | -$39.3M |
|